Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Deleterious BRCA1 Gene Mutation”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Testing effectiveness (Phase 2)WithdrawnNCT03432676
What this trial is testing

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Who this might be right for
ATM Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+7 more
M.D. Anderson Cancer Center
Not applicableLooking for participantsNCT04960839
What this trial is testing

Prophylactic Irradiation to the Contralateral Breast for BCAs Patients

Who this might be right for
Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University 323
Not applicableActive Not RecruitingNCT03546972
What this trial is testing

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationDuctal Breast Carcinoma In Situ+3 more
M.D. Anderson Cancer Center 51
Early research (Phase 1)Active Not RecruitingNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)WithdrawnNCT06392841
What this trial is testing

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Qian Qin
Testing effectiveness (Phase 2)Active Not RecruitingNCT04584255
What this trial is testing

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Who this might be right for
Stage I Breast CancerStage II Breast CancerStage III Breast Cancer+5 more
Dana-Farber Cancer Institute 62
Testing effectiveness (Phase 2)Ended earlyNCT02326844
What this trial is testing

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)Study completedNCT02282345
What this trial is testing

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Who this might be right for
Breast AdenocarcinomaDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+2 more
M.D. Anderson Cancer Center 36
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Not applicableStudy completedNCT03075735
What this trial is testing

Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)

Who this might be right for
Prostate Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III 408
Not applicableStudy completedNCT02608346
What this trial is testing

Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)

Who this might be right for
Women With BRCA1 Germline Deleterious Mutation
Institut Curie 200
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Study completedNCT03845296
What this trial is testing

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationLoss of Heterozygosity+8 more
SWOG Cancer Research Network 64
Testing effectiveness (Phase 2)Ended earlyNCT03140670
What this trial is testing

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Who this might be right for
Pancreatic Cancer
Abramson Cancer Center at Penn Medicine 46
Not applicableActive Not RecruitingNCT02760849
What this trial is testing

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Who this might be right for
Deleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+11 more
M.D. Anderson Cancer Center 374
Testing effectiveness (Phase 2)Active Not RecruitingNCT05033756
What this trial is testing

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Who this might be right for
Malignant Neoplasm of BreastBreast Cancer
Institut fuer Frauengesundheit 11